SCHEMBL629059

SCHEMBL629059

CC(C)N(Cc1ccc(N)cc1)Cc1ccc(N)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 4/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP3A4 P08684 3/20 0.44
GFER P55789 2/20 0.44
TSHR P16473 2/20 0.44
LOXL2 Q9Y4K0 1/20 0.42
ITGB3 P05106 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGAV P06756 1/20 0.39
ITGA5 P08648 1/20 0.39
MAOB P27338 3/20 0.38
MAOA P21397 2/20 0.38
RECQL P46063 2/20 0.37
MAPK1 P28482 2/20 0.37
PSMD14 O00487 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3160936 0.92 MAOB (0.52) MAPTALDH1A1TSHRMAOBMAOA
SCHEMBL3146362 0.82 HDAC1 (0.50) MAPTTDP1ALDH1A1CYP3A4GFER
SCHEMBL27532111 0.80 MAOB (0.53) GFERMAOBMAOAMEN1KMT2A
SCHEMBL5204980 0.80 MAPT (0.46) MAPTTDP1ALDH1A1CYP3A4GFER
SCHEMBL16312137 0.77 PYCR1 (0.46) TDP1ALDH1A1LOXL2MAOBMAOA
SCHEMBL16312132 0.77 SLC6A2 (0.48) MAPTALDH1A1CYP3A4TSHRPYCR1
SCHEMBL3635237 0.76 TSHR (0.54) TDP1ALDH1A1CYP3A4TSHRMAOA
SCHEMBL12261510 0.74 APLNR (0.56) ALDH1A1PYCR1
SCHEMBL3157232 0.74 MAPT (0.53) MAPTTDP1ALDH1A1CYP3A4GFER
SCHEMBL19797774 0.74 TAAR1 (0.61) ALDH1A1HDAC3HDAC6PYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9278922-B2 Anti-viral compounds ABBVIE INC. (US) 2016-03-08 US disclosed
US-9278922-B2 Anti-viral compounds ABBVIE INC. (US) 2016-03-08 US disclosed
US-9278922-B2 Anti-viral compounds ABBVIE INC. (US) 2016-03-08 US disclosed
EP-2419404-B1 ANTI-VIRAL COMPOUNDS ABBVIE INC (US) 2015-11-04 EP disclosed
EP-2419404-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2012-02-22 EP disclosed
WO-2010120935-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-10-21 WO disclosed
WO-2010120935-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-10-21 WO disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 US disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 US disclosed
US-20100267634-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267634-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MAPT 2833/4885TDP1 3922/4885ALDH1A1 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.